PRL3-Zumab in Patients With Advanced Solid Tumors
A phase 2 trial of PRL3-ZUMAB in advanced solid tumours, run by Intra-IMMUSG Pte Ltd, active and no longer recruiting.
Overview
PRL3-Zumab in Patients With Advanced Solid Tumors is a phase 2 interventional study registered as NCT07541001 by Intra-IMMUSG Pte Ltd, with 60 participants enrolled, started 2021-08-30 and due to reach its primary completion in 2026-06-01. Interventions recorded: PRL3-ZUMAB.
Similar pages
not linked directly; found by shared links- TrialPhase II/III Trial of PRL3-Zumab in Advanced Solid Tumor Patients
Shares Intra-IMMUSG, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors
Shares Intra-IMMUSG, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.